Given the high frequency of prostate cancers that exhibit PTEN loss with augmented PI3K–AKT–mTOR signaling, a significant amount of effort has been devoted to exploring PI3K–AKT–mTOR-directed therapies. This evidence concerns the gene MTOR and Familial prostate cancer.